Vorinostat plus chemotherapy for advanced tumors in brain
Treatments studied
Part of Cancer, Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This Phase 1 trial studies how safe and tolerable vorinostat is when combined with chemotherapy for cancers that have come back or are hard to treat, including tumors in the brain or spinal cord. It may help doctors find a better way to treat advanced solid tumors and CNS (brain/spinal cord) cancers.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your age must be 30 or younger (at the start of treatment).
- You must have confirmed cancer that has come back (relapsed) or is hard to treat (refractory), either in the body or in the brain/spinal cord (CNS).
- If you are older than 16, your overall strength must meet a score of at least 50; if under 16, your score must be at least 50.
- You must not have had certain recent treatments: avoid chemotherapy that included irinotecan + temozolomide together, and allow time since your last chemo, radiation, targeted therapy, or stem cell transplant.
- Your blood counts and organ tests must be high enough (enough white blood cells/platelets/hemoglobin and acceptable liver/kidney function).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, silmitasertib, combined with standard chemotherapy for children and young adults with cancers that have come back or not responded to treatment. The goal is to see if this combination can shrink tumors or stop them from growing.
This trial tests whether adding the targeted drug vorasidenib to standard chemotherapy (temozolomide) after radiation helps people with a specific type of advanced brain cancer called IDH-mutant astrocytoma. It is for patients who have not had previous treatments like chemotherapy or radiation and whose tumors have certain genetic features.
This trial tests a combination of two oral medications (vorasidenib and lomustine) for people whose brain tumor (glioma) has come back and has an IDH1 or IDH2 mutation. The goal is to see if this combination is safe and effective in halting or slowing tumor growth.
This trial tests if the drug vorinostat can help prevent graft-versus-host disease (GVHD) in adolescents and young adults undergoing a stem cell transplant for non-cancerous blood, immune, or metabolic disorders. GVHD is a common complication where donor cells attack the recipient's body.
This trial studies whether nivolumab (an immune therapy) plus entinostat (an epigenetic medicine) can help children and teens with high-risk cancers that have come back, worsened, or did not respond to prior treatment. It also looks at specific tumor “biomarkers” to group patients and guide how the study is run.
This trial tests a combination of four drugs (liposomal irinotecan, vincristine, temozolomide, and anlotinib) for children and teens whose solid tumors have come back or haven't responded to standard treatment. The goal is to see if this drug mix can shrink or control the tumors.
Hear when a new Ewing Sarcoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.